



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

Mail Stop 4720

June 8, 2016

John Moore, Esq.
General Counsel
Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301

Re: Array BioPharma Inc.
Form 10-K for the fiscal year ended June 30, 2015
Filed August 21, 2015
Form 10-Q for the quarterly period ended December 31, 2015
Filed February 5, 2016
File No. 001-16633

Dear Mr. Moore:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Joseph McCann for

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance